Y-mAbs Therapeutics, Inc.
YMAB
$4.73
-$0.18-3.67%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 87.69M | 84.55M | 86.55M | 84.50M | 84.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.69M | 84.55M | 86.55M | 84.50M | 84.82M |
| Cost of Revenue | 15.25M | 9.45M | 9.85M | 11.48M | 11.42M |
| Gross Profit | 72.43M | 75.11M | 76.70M | 73.02M | 73.40M |
| SG&A Expenses | 53.93M | 53.37M | 50.66M | 44.70M | 44.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.60M | 112.30M | 114.19M | 109.58M | 106.01M |
| Operating Income | -28.91M | -27.75M | -27.65M | -25.08M | -21.19M |
| Income Before Tax | -29.81M | -23.06M | -23.97M | -20.95M | -20.87M |
| Income Tax Expenses | -146.00K | 801.00K | 642.00K | 721.00K | 561.00K |
| Earnings from Continuing Operations | -29.67 | -23.86 | -24.61 | -21.67 | -21.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.67M | -23.86M | -24.61M | -21.67M | -21.43M |
| EBIT | -28.91M | -27.75M | -27.65M | -25.08M | -21.19M |
| EBITDA | -28.38M | -27.15M | -27.00M | -24.37M | -20.46M |
| EPS Basic | -0.67 | -0.54 | -0.56 | -0.50 | -0.49 |
| Normalized Basic EPS | -0.39 | -0.32 | -0.34 | -0.30 | -0.23 |
| EPS Diluted | -0.67 | -0.54 | -0.56 | -0.50 | -0.49 |
| Normalized Diluted EPS | -0.39 | -0.32 | -0.34 | -0.30 | -0.23 |
| Average Basic Shares Outstanding | 177.30M | 176.06M | 175.05M | 174.69M | 174.58M |
| Average Diluted Shares Outstanding | 177.30M | 176.06M | 175.05M | 174.69M | 174.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
